未知生产厂商
EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity.
EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity.
EGEN-001 inhibits cancer growth by stimulating the immune system and is the first clinical use of a non-viral IL-12 gene therapy approach for treating ovarian cancer. The product, formulated using the company's proprietary TheraPlas(TM) technology, is composed of interleukin-12 gene expression plasmid and a biocompatible delivery polymer. EGEN-001 is designed to increase the local concentration of interleukin-12, a potent anti-cancer cytokine. Unlike standard chemotherapeutic agents, the IL-12 cytokine is known for its ability to inhibit cancer growth by stimulating the immune system.
Investigated for use/treatment in gene therapy and ovarian cancer.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
